These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36707090)

  • 1. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
    McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
    Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
    Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
    Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H
    Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
    Meir J; Abid MA; Abid MB
    Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection.
    Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
    Clin Infect Dis; 2024 Jul; 79(1):86-95. PubMed ID: 38427848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics and impact factors of SARS-CoV-2 infection in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving chimeric antigen receptor T-cell therapy].
    Ge T; Liu H; Wang ZH; Cao Y; Zhang YC; Huang L; Qian WB; Zhou XX
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):825-831. PubMed ID: 38049334
    [No Abstract]   [Full Text] [Related]  

  • 11. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
    Mercadal S; Gomez CA; Lee CJ; Couriel DR
    Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 in New South Wales children during 2021: severity and clinical spectrum.
    Williams P; Koirala A; Saravanos GL; Lopez LK; Glover C; Sharma K; Williams T; Carey E; Shaw N; Dickens E; Sitaram N; Ging J; Bray P; Crawford NW; McMullan B; Macartney K; Wood N; Fulton EL; Lau C; Britton PN
    Med J Aust; 2022 Sep; 217(6):303-310. PubMed ID: 35851698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
    Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell malignancies and COVID-19: a narrative review.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F;
    Clin Microbiol Infect; 2023 Mar; 29(3):332-337. PubMed ID: 36336236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Admission to the Pediatric Intensive Care Unit for SARS-CoV-2 Delta and Omicron Infections.
    Recher M; Leteurtre S; Javouhey E; Morin L; Baudin F; Rambaud J; Mortamet G; Hubert H; Angoulvant F; Levy M;
    J Pediatric Infect Dis Soc; 2023 Apr; 12(4):189-197. PubMed ID: 36786499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
    Hu Y; Tan Su Yin E; Yang Y; Wu H; Wei G; Su J; Cui Q; Jin A; Yang L; Fu S; Zhou J; Qiu L; Zhang X; Liang A; Jing H; Li Y; Blaise D; Mohty M; Nagler A; Huang H
    Curr Res Transl Med; 2020 Aug; 68(3):111-118. PubMed ID: 32620465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.